Last reviewed · How we verify
Empagliflozin Tablets
At a glance
| Generic name | Empagliflozin Tablets |
|---|---|
| Also known as | BI10773, SGLT2-i |
| Sponsor | Kobe University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
- SGLT2i Therapy in Islet Transplantation (SIT) (PHASE4)
- Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
- A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension (PHASE1)
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) (PHASE3)
- Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions (NA)
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empagliflozin Tablets CI brief — competitive landscape report
- Empagliflozin Tablets updates RSS · CI watch RSS
- Kobe University portfolio CI